We are monitoring the impact of COVID-19 on Europe Solid Tumor Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 6301
Share on
Share on

Europe Solid Tumor Market Research Report – Segmented By Disease, Drugs and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2020 to 2025)

Pulished: February, 2020
ID: 6301
Pages: 145

Europe Solid Tumor Market (2020 to 2025)

The Solid Tumor Market in Europe is estimated to hike at a robust CAGR during the forecast period.

Solid tumors are formed due to the aggregation of abnormal tissues that do not comprise of any cyst or liquid areas within.

They are mainly of two types- malignant and benign. Most of the solid tumors are treated via radiotherapy, chemotherapy or surgery. Various chemotherapeutic drugs are available in the market along with a ripe pipeline of drugs that will soon be commercialized.

Some of the major driving factors for the growth of this market include rise in the number of cancer cases, increasing incidences of several cases of solid tumors. Due to rise in the number of cases, there has been an increasing demand for highly effective chemotherapeutic agents which in turn drives the market. Many companies are investing in various R&D projects related to therapeutics which fuels the market growth.

However, increasing generic products, high cost of therapy, increasing cost of R&D and various drugs going off patent, are turning out to be restraints for the market.

This research report has been segmented and sub-segmented into the following categories:

By Disease

  • Breast cancer        
  • Lung cancer           
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Others      

By Drugs

  • Carboplatin            
  • Cisplatin  
  • Gemcitabine          
  • Paclitaxel
  • Doxorubicin           
  • Bevacizumab         
  • Erlotinib   
  • Sunitinib  
  • Everolimus           
  • Docetaxel            
  • Abiraterone         
  • Abiraterone acetate         
  • Cabazitaxel

By Country

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regionally, Europe is the second largest market due to a large geriatric population which contributes heavily to the growth of the solid tumor market.

Companies dominating the European Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                   

               1.3 Base Currency, Base Year and Forecast Periods                           

               1.4 General Study Assumptions                  

2. Research Methodology                                          

               2.1 Introduction               

               2.2 Research Phases                      

                              2.2.1 Secondary Research            

                              2.2.2 Primary Research  

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation   

               2.3 Analysis Design                         

               2.4 Study Timeline                          

3. Overview                                     

               3.1 Executive Summary                 

               3.2 Key Inferences                          

               3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                        

               4.1 Market Drivers                         

               4.2 Market Restraints                    

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market                 

5. Market Segmentation                              

               5.1 Disease                       

                              5.1.1 Introduction           

                              5.1.2 Breast cancer         

                              5.1.3 Lung cancer            

                              5.1.4 Colorectal cancer  

                              5.1.5 Prostate cancer     

                              5.1.6 Cervical cancer      

                              5.1.7 Others       

                              5.1.8  Y-o-Y Growth Analysis, By disease 

                              5.1.9  Market Attractiveness Analysis, By disease 

                              5.1.10  Market Share Analysis, By disease

               5.2 Drugs                           

                              5.2.1 Introduction           

                              5.2.2 Carboplatin             

                              5.2.3 Cisplatin   

                              5.2.4 Gemcitabine           

                              5.2.5 Paclitaxel 

                              5.2.6 Doxorubicin            

                              5.2.7 Bevacizumab          

                              5.2.8 Erlotinib    

                              5.2.9 Sunitinib   

                              5.2.10 Everolimus            

                              5.2.11 Docetaxel             

                              5.2.12 Abiraterone          

                              5.2.13 Abiraterone acetate          

                              5.2.14 Cabazitaxel           

                              5.2.15 Y-o-Y Growth Analysis, By Drugs   

                              5.2.16 Market Attractiveness Analysis, By drugs   

                              5.2.17 Market Share Analysis, By drugs    

6. Geographical Analysis                              

               6.1 Introduction               

                              6.1.1 Regional Trends     

                              6.1.2 Impact Analysis      

                              6.1.3 Y-o-Y Growth Analysis         

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By disease

                                             6.1.3.3 By drugs

                              6.1.4  Market Attractiveness Analysis       

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By disease

                                             6.1.4.3 By drugs

                              6.1.5  Market Share Analysis        

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By disease

                                             6.1.5.3 By drugs

               6.2 U.K                

               6.3 Spain                            

               6.4 Germany                     

               6.5 Italy                             

               6.6 France                         

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis              

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services  

                              7.2.5 Competitive Rivalry within the Industry        

8. Market Leaders' Analysis                                        

               8.1 Abbott Laboratories                

                              8.1.1 Overview  

                              8.1.2 Product Analysis    

                              8.1.3 Financial analysis   

                              8.1.4 Recent Developments         

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View           

               8.2 Boehringer Ingelheim GmbH                

               8.3 Baxter International                

               8.4 Bristol-Myers Squibb Company                           

               8.5 F. Hoffmann-La Roche Ltd.                  

               8.6 Eli Lilly and Company                             

               8.7 Johnson & Johnson                 

               8.8 GlaxoSmithKline plc                 

               8.9 Kyowa Hakko Kirin Co., Ltd.                 

               8.10 Sanofi                        

9. Competitive Landscape                                          

               9.1 Market share analysis                            

               9.2 Merger and Acquisition Analysis                         

               9.3 Agreements, collaborations and Joint Ventures                           

               9.4 New Product Launches                          

10. Market Outlook and Investment Opportunities                                           

Appendix                                          

               a) List of Tables                

               b) List of Figures              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms Disease and Drug along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Europe Solid Tumor Market, By Disease, From 2020 to 2025 (USD Million)
  2. Europe Breast cancer Market, By Region, From 2020 to 2025 (USD Million)
  3. Europe Lung cancer Market, By Region, From 2020 to 2025 (USD Million)
  4. Europe Liver cancer Market, By Region, From 2020 to 2025 (USD Million)
  5. Europe Colorectal cancer Market, By Region, From 2020 to 2025 (USD Million)
  6. Europe Cervical cancer Market, By Region, From 2020 to 2025 (USD Million)
  7. Europe Prostate cancer Market, By Region, From 2020 to 2025 (USD Million)
  8. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  9. Europe Solid Tumor Market, By Drugs, From 2020 to 2025 (USD Million)
  10. Europe Carboplatin Market, By Region, From 2020 to 2025 (USD Million)
  11. Europe Cisplatin Market, By Region, From 2020 to 2025 (USD Million)
  12. Europe Doxorubicin Market, By Region, From 2020 to 2025 (USD Million)
  13. Europe Paclitaxel Market, By Region, From 2020 to 2025 (USD Million)
  14. Europe Erlotinib Market, By Region, From 2020 to 2025 (USD Million)
  15. Europe Suntinib Market, By Region, From 2020 to 2025 (USD Million)
  16. Europe Everolimus Market, By Region, From 2020 to 2025 (USD Million)
  17. Europe Docetaxel Market, By Region, From 2020 to 2025 (USD Million)
  18. Europe Abiraterone acetate Market, By Region, From 2020 to 2025 (USD Million)
  19. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  20. U.K. Solid Tumor Market, By Disease, From 2020 to 2025 (USD Million)
  21. U.K. Solid Tumor Market, By Drugs, From 2020 to 2025 (USD Million)
  22. Germany Solid Tumor Market, By Disease, From 2020 to 2025 (USD Million)
  23. Germany Solid Tumor Market, By Drugs, From 2020 to 2025 (USD Million)
  24. France Solid Tumor Market, By Disease, From 2020 to 2025 (USD Million)
  25. France Solid Tumor Market, By Drugs, From 2020 to 2025 (USD Million)
  26. Italy Solid Tumor Market, By Disease, From 2020 to 2025 (USD Million)
  27. Italy Solid Tumor Market, By Drugs, From 2020 to 2025 (USD Million)
  28. Spain Solid Tumor Market, By Disease, From 2020 to 2025 (USD Million)
  29. Spain Solid Tumor Market, By Drugs, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample